Mirae Asset Global Investments Co. Ltd. Makes New Investment in Kenvue Inc. $KVUE

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 614,092 shares of the company’s stock, valued at approximately $10,845,000.

Several other institutional investors have also made changes to their positions in the business. Vise Technologies Inc. raised its position in shares of Kenvue by 16.0% during the third quarter. Vise Technologies Inc. now owns 35,217 shares of the company’s stock worth $622,000 after acquiring an additional 4,864 shares during the last quarter. Cidel Asset Management Inc. increased its stake in shares of Kenvue by 5.4% during the 3rd quarter. Cidel Asset Management Inc. now owns 19,288 shares of the company’s stock worth $341,000 after purchasing an additional 988 shares during the last quarter. Americana Partners LLC grew its stake in Kenvue by 3.7% in the 3rd quarter. Americana Partners LLC now owns 51,160 shares of the company’s stock valued at $903,000 after buying an additional 1,825 shares during the last quarter. North Dakota State Investment Board raised its holdings in shares of Kenvue by 2.8% during the 3rd quarter. North Dakota State Investment Board now owns 58,063 shares of the company’s stock worth $1,025,000 after buying an additional 1,558 shares in the last quarter. Finally, Generali Asset Management SPA SGR boosted its stake in shares of Kenvue by 5.4% during the third quarter. Generali Asset Management SPA SGR now owns 237,891 shares of the company’s stock valued at $4,201,000 after purchasing an additional 12,290 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE opened at $19.31 on Thursday. Kenvue Inc. has a one year low of $14.06 and a one year high of $20.13. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The stock has a 50 day moving average price of $18.41 and a 200 day moving average price of $18.22. The stock has a market capitalization of $37.09 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Friday, October 30th. The company reported $0.29 EPS for the quarter, hitting analysts’ consensus estimates of $0.29. The company had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The firm’s revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 earnings per share. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date of this dividend was Monday, September 21st. Kenvue’s dividend payout ratio (DPR) is presently 95.45%.

Analyst Ratings Changes

Several research analysts have issued reports on the company. HSBC cut their price target on Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Barclays lifted their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, UBS Group boosted their target price on Kenvue from $19.00 to $20.00 and gave the stock a “neutral” rating in a research report on Monday. Ten research analysts have rated the stock with a Hold rating. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $19.29.

Kenvue Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.